Zoetis (NYSE:ZTS) Stock, Quote.Headers.trade-ideas

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Earnings

Mid Cap

News

Markets

Analyst Ratings

Trading Ideas

CORT

Corcept Therapeutics (NASDAQ: CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 15.7% gain over the past four weeks.

Corcept Moves 6.5% Higher: Will This Strength Last?

starbucks-1972319_1920

Price Target

Pre-Market Outlook

AZPN

FERG

LBPH

NMIH

SBUX

WDAY

Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday

JimCramer.Shutterstock

Long Ideas

Media

PRCT

Jim Cramer discusses PROCEPT BioRobotics, Zoetis, Target and Consolidated Edison. &#34;

Jim Cramer Says This Retailer Yields 3%: &#39;Which Is Quite Good&#39;

Zoetis Inc

BMO ST TRM US TRY BD INX USD UNT ETF

Ztest Electronics Inc

Corcept Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 15.7% gain over the past four weeks.
The company&#39;s sole marketed drug, Korlym, approved for treating Cushing&#39;s syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing&#39;s syndrome is expected to be filed in the fourth quarter of 2024. The ongoing progress with Korlym and relacorilant could be the reason for the share price rally.
This drug developer is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -7.1%. Revenues are expected to be $171.04 million, up 38.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Corcept, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CORT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Corcept is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Zoetis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zts#NYSE">ZTS</a>), finished the last trading session 0.4% higher at $196.48. ZTS has returned 6.6% over the past month.
For Zoetis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.46. This represents a change of +7.4% from what the company reported a year ago. Zoetis currently has a Zacks Rank of #2 (Buy).
<a href="https://www.zacks.com/stock/news/2338319/corcept-cort-moves-6-5-higher-will-this-strength-last?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2338319">To read this article on Zacks.com click here.</a>

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised the price target for Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) from  $200 to $217. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Aspen Technology shares gained 3.3% to close at $233.54 on Tuesday. <a href="https://www.benzinga.com/quote/AZPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for NMI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) from $40 to $48. RBC Capital analyst Scott Heleniak upgraded the stock from Sector Perform to Outperform. NMI Holdings shares fell 1.4% to close at $41.15 on Tuesday. <a href="https://www.benzinga.com/quote/NMIH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. lifted Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) price target from $60 to $80. HC Wainwright &amp; Co. analyst Patrick Trucchio maintained a Buy rating. Longboard Pharmaceuticals shares fell 10.3% to close at $27.58 on Tuesday. S<a href="https://www.benzinga.com/quote/LBPH/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Benchmark increased Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) price target from $115 to $120. Benchmark analyst Reuben Garner maintained a Buy rating. Belden shares gained 2.9% to close at $106.29 on Tuesday. <a href="https://www.benzinga.com/quote/BDC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $112 to $118. B of A Securities analyst Sara Senatore maintained a Buy rating. Starbucks rose 0.1% to close at $96.44 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $350 to $300. Needham analyst Scott Berg maintained a Buy rating. Workday shares fell 0.4% to close at $248.12 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) price target from $222 to $225. Baird analyst David Manthey maintained an Outperform rating. Ferguson Enterprises shares gained 5% to close at $207.06 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from $347 to $345. B of A Securities analyst Ken Hoexter maintained a Buy rating. FedEx shares rose 1.6% to close at $297.34 on Tuesday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) price target from $262 to $280. Goldman Sachs analyst Alex Scott maintained a Buy rating. Progressive shares rose 0.2% to close at $256.91 on Tuesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) price target from $200 to $210. Stifel analyst Jonathan Block maintained a Buy rating. Zoetis shares rose 0.8% to close at $195.71 on Tuesday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-1024x526.png" alt="" class="wp-image-553956" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

Analysts' ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $210.83, a high estimate of $225.00, and a low estimate of $200.00. This upward trend is evident, with the current average reflecting a 5.94% increase from the previous average price target of $199.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726664459_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Zoetis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zoetis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zoetis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zoetis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>All You Need to Know About Zoetis</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Understanding the Numbers: Zoetis's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Zoetis's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.3%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin excels beyond industry benchmarks, reaching 26.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 12.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zoetis's ROA stands out, surpassing industry averages. With an impressive ROA of 4.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zoetis's debt-to-equity ratio is below the industry average. With a ratio of 1.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Zoetis Stands With Analysts

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and raises the price target from $200 to $210.

Stifel Maintains Buy on Zoetis, Raises Price Target to $210

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 7.14% on an annualized basis producing an average annual return of 17.81%. Currently, Zoetis has a market capitalization of $83.85 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,160.31 today based on a price of $185.07 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725544824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported a &#8220;<a href="https://www.benzinga.com/news/earnings/24/08/40482203/target-q2-earnings-revenue-and-profit-beat-digital-sales-boost-annual-profit-outlook-hiked">very, very good&#8221; quarter</a>. 
&#8220;It does yield 3%, which is actually quite good,&#8221; he added.
On Aug. 21, Target posted stellar second-quarter results outperformed earnings and sales expectations and prompted an optimistic boost to its full-year profit outlook. 
Quarterly adjusted earnings per share totaled $2.57 (+40%), beating the street view of $2.20. Target reported sales of $25.45 billion (+2.7%), exceeding the analyst consensus of $25.229 billion.
See Also: <a href="https://www.benzinga.com/news/earnings/24/03/37413962/how-to-earn-500-a-month-from-target-stock-ahead-of-q4-print">How To Earn $500 A Month From Target Stock Ahead Of Q4 Print</a>
Cramer also likes Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>).
On Aug. 6, Zoetis reported better-than-expected second-quarter financial results and raised its <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">2024 guidance above estimates</a>. The animal health company reported second-quarter revenue of $2.36 billion, up 8% year-over-year on reported and 11% on an operational basis, beating the consensus of $2.31 billion.
When asked about PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), he said, &#8220;It's been a rocket, but I think if you're going to be in robotics, you have to be in ISRG.&#8221;
On Sept. 3, Truist Securities analyst Richard Newitter maintained PROCEPT BioRobotics with a Buy and raised the price target from $74 to $95.
&#8220;I've liked Con Ed for, I don't know, maybe 70 points,&#8221; Cramer said when asked about Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>). &#8220;As long as it's around, above three, I think the stock can still project itself even higher.&#8221;
On Aug. 1, Consolidated Edison reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 57 cents per share. The company reported quarterly sales of $3.22 billion which beat the analyst consensus estimate of $3.18 billion.
Price Action:
<ul>
<li>PROCEPT BioRobotics shares fell 5% to settle at $75.06 on Tuesday.</li>
<li>Zoetis shares gained 0.04% to close at $183.57.</li>
<li>Target shares fell 1.2% to close at $151.80 during Tuesday's session.</li>
<li>Consolidated Edison shares rose 1.7% to settle at $103.28 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40700996/dow-tumbles-over-600-points-nasdaq-dips-3-amid-plunge-in-nvidia-fear-index-remains-in-greed-zone">Dow Tumbles Over 600 Points, Nasdaq Dips 3% Amid Plunge In Nvidia: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Jim Cramer Says This Retailer Yields 3%: 'Which Is Quite Good'

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and maintains $200 price target.

Stifel Maintains Buy on Zoetis, Maintains $200 Price Target

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 6.91% on an annualized basis producing an average annual return of 17.73%. Currently, Zoetis has a market capitalization of $82.47 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $511.32 today based on a price of $182.03 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724430670_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today

Zoetis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) short percent of float has fallen 11.21% since its last report. The company recently reported that it has 4.65 million shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zoetis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723841121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoetis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zoetis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zoetis's peer group average for short interest as a percentage of float is 4.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Zoetis?

In the latest quarter, 4 analysts provided ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $213.75, a high estimate of $225.00, and a low estimate of $200.00. Witnessing a positive shift, the current average has risen by 7.77% from the previous average price target of $198.33.
<img src="https://www.benzinga.com/files/images/story/2024/1723658434_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Zoetis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zoetis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zoetis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Zoetis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>Delving into Zoetis's Background</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Understanding the Numbers: Zoetis's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Zoetis's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 8.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.43% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 12.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zoetis's ROA stands out, surpassing industry averages. With an impressive ROA of 4.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zoetis's debt-to-equity ratio is below the industry average. With a ratio of 1.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Zoetis

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $195 to $210.

Piper Sandler Maintains Overweight on Zoetis, Raises Price Target to $210

BTIG analyst Mark Massaro maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and raises the price target from $220 to $225.

BTIG Maintains Buy on Zoetis, Raises Price Target to $225

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 18.17%. Currently, Zoetis has a market capitalization of $83.03 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $540.13 today based on a price of $183.26 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723489214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On Tuesday, Zoetis Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) stock is trading higher after the company reported better-than-expected second-quarter financial results and raised its 2024 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40183215/zoetis-announces-second-quarter-2024-results" rel="noreferrer noopener">guidance above estimates</a>.
The animal health company reported second-quarter revenue of $2.36 billion, up 8% year-over-year on reported and 11% on an operational basis,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38577408/zoetis-announces-first-quarter-2024-results" rel="noreferrer noopener">beating the&nbsp;consensus of $2.31 billion</a>.
&#8220;We achieved 12% revenue growth in the U.S. and 10% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 12% and 9% respectively,&#8221; said Kristin Peck, CEO.
Related: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38223218/animal-health-giant-zoetis-stock-crumbles-possible-side-effect-of-its-pet-arthritis-pain-drugs-si" rel="noreferrer noopener">Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats</a>.
Revenue in the U.S. segment was $1.3 billion, up 12%.&nbsp;
Sales of companion animal products increased by 13%, driven by the company&#8217;s monoclonal antibody products for osteoarthritis (OA) pain, Librela&nbsp;for dogs, and Solensia for cats. Simparica Trio, the company&#8217;s flea, tick, and heartworm combination product also contributed to the growth.
Sales of livestock products increased 11% in the quarter.
Growth in cattle and swine products was driven primarily by a soft prior year comparison due to the timing of supply of ceftiofur.
Revenue in the&nbsp;International segment&nbsp;stood at $1.0 billion, rising by 4%&nbsp;on a reported basis and by 10% operationally in the quarter.
Adjusted net income for the second quarter of 2024 was $711 million, or $1.56 per diluted share, an increase of 9% and 11%, respectively, on a reported basis and 18%&nbsp;and 20%, respectively, on an operational basis, beating the consensus of $1.49.
Guidance: Zoetis raised its 2024 sales guidance to $9.1 billion to $9.25 billion, from its <a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38585569/why-animal-health-focused-zoetis-shares-are-trading-higher-today" rel="noreferrer noopener">prior guidance of $9.05 billion to $9.2 billion</a> and the consensus of $9.15 billion.
The company expects 2024 adjusted EPS of $5.78-$5.88 versus prior guidance of $5.71-$5.81 and the consensus of $5.77.
William Blair writes, &#8220;In sum, Zoetis continues to benefit from the breadth of its portfolio innovation, and we think this momentum should continue through 2024-plus aided by some key areas like companion animal pain therapy, dermatology, and parasiticides.&#8221; The analyst maintains <a target="_blank" href="https://www.benzinga.com/quote/ZTS/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
William Blair adds companion animal operations grew by 12% despite an 11% comparison and ongoing macroeconomic concerns. This performance should instill confidence in the business&#8217;s trajectory through 2024 and beyond.
Price Action: ZTS stock is up 5.82% at $185.01 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40192182/listerine-maker-kenvues-stock-soars-on-strong-q2-sales-from-its-essential-health-unit-reaffirms-ann" target="_blank" rel="noreferrer noopener">Listerine-Maker Kenvue&#8217;s Stock Soars On Strong Q2 Sales From Its Essential Health Unit, Reaffirms Annual Guidance</a>.</li>
</ul>
Photo by huoadg5888 via <a href="https://pixabay.com/photos/pets-cat-dog-animals-mammals-3715733/">Pixabay</a>

Analyst Color

Guidance

Health Care

Movers

General

Animal Health Firm Zoetis Clocks Strong Q2 Earnings, Companion Animal Operations Boost Confidence For 2024

WIIM

Zoetis shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 guidance above estimates.

Zoetis Expects 2024 Adjusted EPS Of  $5.78-$5.88 Versus Prior Guidance Of $5.71-$5.81 And Consensus Of $5.77

FINANCIAL GUIDANCE
Zoetis is raising its full year reported 2024 guidance due to the company's strong first half and the underlying strength in companion animal.
<ul>
<li>Revenue between $9.100 billion to $9.250 billion (operational growth of 9% to 11%)</li>
<li>Reported net income between $2.450 billion to $2.490 billion</li>
<li>Adjusted net income between $2.640 billion to $2.690 billion (operational growth of 13.5% to 15.5%)</li>
<li>Reported diluted EPS of $5.35 to $5.45</li>
<li>Adjusted diluted EPS between $5.78 to $5.88</li>
</ul>

Zoetis Raises 2024 Revenue Guidance Of $9.1B-$9.25B Versus Prior Guidance Of $9.05B-$9.2B And Consensus Of $9.145B

Zoetis Q2 2024 Adj. EPS $1.56 Beats $1.49 Estimate, Sales $2.361B Beat $2.311B Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Stifel boosted the price target for Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) from $180 to $200. Stifel analyst Jonathan Block maintained a Buy rating. Zoetis shares fell 3% to trade at $175.38 on Monday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised the price target for IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) from $260 to $288. JP Morgan analyst Anne Samuel maintained an Overweight rating. IQVIA shares fell 3.8% to trade at $232.55 on Monday. <a href="https://www.benzinga.com/quote/IQV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo increased Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) price target from $185 to $195. Wells Fargo analyst Sam Reid maintained an Overweight rating. Lennar shares fell 4.5% to trade at $166.69 on Monday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna raised the price target for Cloudflare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) from $80 to $85. Susquehanna analyst Aaron Samuels maintained a Neutral rating. Cloudflare shares fell 4.8% to trade at $75.62 on Monday. <a href="https://www.benzinga.com/quote/INTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $1,025 to $990. Citigroup analyst Atif Malik maintained a Buy rating. Lam Research shares fell 2.1% to trade at $747.01 on Monday. <a href="https://www.benzinga.com/quote/LRCX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) price target from $60 to $54. Goldman Sachs analyst Ben Miller maintained a Buy rating. DraftKings shares fell 3.2% to trade at $31.01 on Monday. <a href="https://www.benzinga.com/quote/DKNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised the price target for Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) from $53 to $57. BMO Capital analyst James Thalacker maintained a Market Perform rating. Dominion Energy shares fell 1.3% to trade at $55.38 on Monday.<a href="https://www.benzinga.com/quote/D/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>JP Morgan boosted The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) price target from $377 to $400. JP Morgan analyst Christopher Horvers maintained an Overweight rating. Home Depot shares fell 1.6% to trade at $349.80 on Monday. <a href="https://www.benzinga.com/quote/HD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) price target from $125 to $90. RBC Capital analyst Luca Issi downgraded the stock from Outperform to Sector Perform. Moderna shares fell 2.8% to trade at $84.19 on Monday.<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Macquarie raised Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $46 to $50. Macquarie analyst Aaron Lee maintained an Outperform rating. Roblox shares dipped 9% to trade at $35.50 on Monday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/markets/24/08/40142776/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a></li>
</ul>

DKNG

INTC

LRCX

MRNA

RBLX

Home Depot To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and raises the price target from $180 to $200.

Stifel Maintains Buy on Zoetis, Raises Price Target to $200

Zoetis (ZTS) continues to showcase its solid market position and commitment to innovation across its diverse portfolio, introducing advanced products that meet the evolving needs of animal health. Given its robust fundamentals and industry leadership, let's find out if ZTS is a solid choice for those looking to invest in the animal health sector... Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), the world's leading animal health company, reported outstanding results for the second quarter of 2024 and raised its full-year guidance. The company's <a href="https://investor.zoetis.com/news/news-details/2024/Zoetis-Announces-Second-Quarter-2024-Results/default.aspx#:~:text=The%20company%20reported%20revenue%20of,the%20second%20quarter%20of%202023.">revenue came in at $2.36 billion</a>, surpassing analysts' estimate of $2.31 billion. It posted adjusted net income per share of $1.56 for the second quarter, compared to the consensus estimate of $1.48.
The company achieved 12% revenue growth in the U.S. and 10% operational revenue growth internationally, with its companion animal and livestock portfolios showing impressive global operational growth of 12% and 9%, respectively.
"Our excellent first half across key franchises, including osteoarthritis (OA) pain, Simparica and key dermatology, is a testament to our commitment to deliver breakthrough innovations that address our customers' unmet needs and our differentiated execution," said Kristin Peck, Chief Executive Officer of Zoetis.
"I look forward to continuing our momentum into the second half of the year where we will remain focused on executing our strategy, building trust and preference for our best-in-class products and delivering value to shareholders," Peck added.
Zoetis continues to advance innovation and animal care worldwide. The company received approval in Canada for Alpha Ject Micro&#xAE; 7 ISA, the latest version of its combination vaccine for Atlantic Salmon, now offering enhanced protection against Infectious Salmon Anaemia Virus (ISA).
Additionally, Simparica and Simparica Trio were approved in Canada for treating and controlling infestations of Asian longhorned ticks in dogs. ZTS also received approval in Japan for Draxxin&#xAE; KP, an injectable for treating bacterial pneumonia in cattle. Further, the company is strengthening its Diagnostic offerings with the expected launch of a new point-of-care hematology analyzer, Vetscan&#xAE; Opticell&#x2122;, in the second half of 2024.
After a solid first half and the underlying strength in companion animal, Zoetis raised its full-year 2024 revenue guidance to $9.10 - $9.25 billion, with an adjusted EPS of $5.78 to $5.88. The company increased its full-year operational revenue growth to 9% - 11% and operational growth in adjusted net income to 13.5% - 15.5%.
Shares of ZTS have gained 5.9% over the past three months to close the last trading session at $180.90.
Let's look at factors that could influence ZTS' performance in the upcoming months.
Robust Financials
For the second quarter that ended June 30, 2024, ZTS' total revenue increased 8.3% year-over-year to $2.36 billion. Its non-GAAP <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 7.4% from the year-ago value to $1.69 billion. Non-GAAP net income and earnings per common share attributable to Zoetis were $711 million and $1.56, up 9% and 10.6% from the prior year's quarter, respectively.
Favorable Analyst Estimates
Analysts expect ZTS' revenue for the third quarter (ending September 2024) to grow 6.4% year-over-year to $2.29 billion. The consensus EPS estimate of $1.46 for the ongoing quarter indicates an improvement of 7.7% year-over-year. Further, the company has topped consensus revenue and EPS estimates in three of the trailing four quarters, which is impressive.
For the fiscal year ending December 2024, Street expects Zoetis' revenue and EPS to increase 7.5% and 9.5% from the previous year to $9.18 billion and $5.83, respectively. The company's revenue and EPS for the fiscal year 2025 are expected to grow 6.7% and 10.5% year-over-year to $9.80 billion and $6.44, respectively.
High Profitability
ZTS' trailing-12-month gross profit margin of 70.01% is 21.9% higher than the industry average of 57.41%. Likewise, the stock's trailing-12-month EBITDA margin of 40.89% is 603.3% higher than the industry average of 5.81%. Moreover, its trailing-12-month levered FCF margin of 18.97% is significantly higher than the industry average of 1.31%.
Further, the stock's trailing-12-month ROCE, ROTC, and ROTA of 48.88%, 17.38%, and 16.55% favorably compared to the industry averages of negative 41.24%, negative 19.81%, and negative 27.50%, respectively. Its trailing-12-month CAPEX/Sales of 6.90% is 109.9% higher than the industry average of 3.29%.
POWR Ratings Reflect Promise
ZTS' sound fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ZTS has a B grade for Quality, consistent with its higher-than-industry profitability. The stock has a B grade for Stability, justified by its 60-month beta of 0.86.
Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, ZTS is ranked #42 out of 157 stocks.
Beyond what I have stated above, we have also given ZTS grades for Momentum, Value, Growth, and Sentiment. Get all ZTS ratings <a href="https://stocknews.com/stock/ZTS/">here</a>.
Bottom Line
ZTS delivered an outstanding second-quarter performance, showcasing the high demand for its innovative products and its ability to capture and expand markets. Following a solid first half, the company is well-poised to continue its momentum into the year's second half, focusing on executing its strategy and building trust and preference for its best-in-class products.
Given robust financials, accelerating profitability, and a bright long-term outlook, ZTS could be an ideal buy for substantial returns.
How Does Zoetis Inc. (ZTS) Stack Up Against Its Peers?
While TWLO has an overall POWR Rating of B, investors could also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry with an A (Strong Buy) rating: Novartis AG ADR (<a href="https://stocknews.com/stock/NVS/">NVS</a>), AstraZeneca PLC ADR (<a href="https://stocknews.com/stock/AZN/">AZN</a>), and Merk &amp; Co. Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>).
To explore more A or B-rated medical stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZTS shares were unchanged in premarket trading Monday. Year-to-date, ZTS has declined -7.66%, versus a 19.02% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/zts-mrk-nvs-azn-should-you-buy-zoetis-amid-rising-pet-care-demand/>Should You Buy Zoetis Amid Rising Pet Care Demand?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Should You Buy Zoetis Amid Rising Pet Care Demand?

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $200.00. The compa...

Stifel Nicolaus Reaffirms Their Buy Rating on Zoetis (ZTS)

50 High Quality Dividend Stocks To Own For The Long Term

Dividend Champion, Contender, And Challenger Highlights: Week Of September 1

My Top 15 High Growth Dividend Stocks For September 2024

Zoetis Inc (ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

The pet care industry is expected to witness immense growth owing to a surge in pet adoptions, veterinary innovations, and rising disposable income. Thus, one could scoop up shares of fundamentally solid pet-care stocks with tail-wagging potential, like Zoetis (ZTS), Chewy (CHWY), and PetIQ (PETQ). Read more… The pet care industry is witnessing remarkable growth driven by a surge in global pet adoptions and significant advancements in veterinary care. Concurrently, the increased investment by pet owners in care and accessories is expected to bolster strong growth prospects for the sector.
Given this backdrop, investors could consider loading up on shares of fundamentally sound pet care stocks Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>), and  PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>) that seem well positioned to capitalize on the industry tailwinds.
In recent times, pet adoption has increased drastically, and the trend continues. A substantial number of American households own a pet, with dogs being the most popular. <a href="https://www.forbes.com/advisor/pet-insurance/pet-adoption-statistics/">Pet ownership</a> is increasing particularly amongst young generations, with millennials having the highest share of pet owners at 33%.
Advancements in technology are also transforming veterinary medicine, leading to improved diagnostic capabilities, innovative treatment options, and enhanced medical devices. Innovations like telemedicine, digital imaging, minimally invasive surgeries, and advanced laboratory diagnostics have significantly upgraded the quality of animal care and broadened the scope of veterinary services.
According to a Grand View Research study, the U.S. veterinary medicine market is expected to grow at <a href="https://www.grandviewresearch.com/industry-analysis/us-veterinary-medicine-market-report">a CAGR of 6.8%</a> from 2024 to 2030. This growth is projected to push the market to a substantial $21.80 billion, reflecting the increasing demand for advanced veterinary care.
Moreover, an increase in disposable income has further fueled higher pet ownership rates, prompting greater investment in pet care products like accessories, health items, and fashion. According to the Bureau of Economic Analysis data, disposable personal income <a href="https://www.bea.gov/news/2024/personal-income-and-outlays-july-2024">rose by $54.8 billion</a> or 0.3% in July 2024.
Looking forward, as per a report by Mordor Intelligence, the pet care market is expected to reach $24.59 billion by 2029, expanding at a <a href="https://www.mordorintelligence.com/industry-reports/pet-care-market">CAGR of 4.2%</a>.
Given these positive trends, let's discuss the fundamentals of three pet-care stocks, starting with #3.
Stock #3: Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>)
ZTS develops, manufactures, and commercializes medicines, vaccines, and diagnostic products and services for animal health. It operates in eight core species and seven major product categories, with products sold in 45 countries and over 100 countries. The company operates through two segments: United States and International.
On April 28, ZTS <a href="https://investor.zoetis.com/news/news-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx">announced its definitive agreement</a> with Phibro Animal Health Corporation (<a href="https://stocknews.com/stock/PAHC/">PAHC</a>), a global leader in animal health and nutrition. As part of this deal, PAHC will acquire ZTS' medicated feed additive (MFA) product portfolio, select water-soluble products, and related assets for around $350 million.
The transaction would allow ZTS to streamline its focus on core areas while unlocking capital for strategic growth opportunities.
For the fiscal 2024 second quarter that ended on June 30, 2024, ZTS' revenue increased 8.3% year-over-year to $2.36 billion. Its non-GAAP gross profit grew 7.4% from the year-ago value to $1.69 million.
In addition, non-GAAP net income attributable to ZTS came in at $711 million or $1.56 per share, indicating a year-over-year growth of 9% and 10.6%, respectively.
Analysts expect ZTS' revenue for the fiscal third quarter (ending September 2024) to increase 6.4% year-over-year to $2.29 billion. Meanwhile, its EPS for the same quarter is expected to grow 7.7% from the prior year's period to $1.46. Furthermore, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of ZTS have surged 3.7% in the past month and 9% in the past three months to close the last trading session at $187.33.
ZTS' bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ZTS has a B grade for Quality and Stability. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, the stock is ranked #39 out of 158 stocks.
<a href="https://stocknews.com/stock/ZTS/">Click here</a> to access additional ZTS ratings for Sentiment, Momentum, Growth, and Value.
Stock #2: Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>)
CHWY operates as a pure-play e-commerce business. It offers pet food, treats, supplies, and medications, along with other pet health products. The company also provides pet services for dogs, cats, fish, birds, small pets, horses, and reptiles. These are available through its retail websites and mobile applications.
For the fiscal 2024 second quarter ended on July 28, 2024, CHWY's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.6% year-over-year to $2.86 billion. Its gross profit rose 7% from the year-ago value to $843.84 million. Additionally, the company's adjusted EBITDA of $144.84 million indicates an increase of 64.3% from the prior year's quarter.
Furthermore, the company's adjusted net income and adjusted EPS came in at $104.79 million and $0.24, up 62.3% and 60% from the previous year's period, respectively.
For the fiscal 2025 third quarter ending October 2024, CHWY's revenue and EPS are expected to increase 4.2% and 49.9% year-over-year to $2.85 billion and $0.22, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters, which is impressive.
Shares of CHWY have gained 22.1% over the past three months and 53.3% over the past six months to close the trading session at $27.15.
CHWY's sound fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CHWY has an A grade for Growth and a B grade for Quality and Sentiment.
Within the A-rated <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry, CHWY is ranked #15 among the 52 stocks.
In addition to the POWR Ratings we've stated above, we also have CHWY's ratings for Stability, Value, and Momentum. Get all CHWY ratings <a href="https://stocknews.com/stock/CHWY/">here</a>.
Stock #1: PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>)
PETQ is a pet medication and wellness company that offers veterinary products and services. The company's Products segment distributes value-branded and third-party products for dogs and cats. Meanwhile, the Services segment offers diagnostic tests, vaccinations, and specialty medications.
On August 7, PETQ <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-enters-definitive-agreement-be-acquired-bansk-group">announced its acquisition</a> by Bansk Group, a consumer-focused private investment firm. Bansk will acquire all outstanding shares of PETQ's common stock at $31.00 per share, valuing the transaction at approximately $1.5 billion.
Cord Christensen, Founder, Chairman, and CEO of PETQ, stated that the Board considers this transaction a positive outcome for both the company and its stockholders.
On March 14, PETQ announced the <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-celebrates-expansion-mintiesr-dental-treats-brand">launch of its new product</a>, Minties&#xAE; dental treats, designed for tiny/small, medium, and large-sized dogs, as well as cats. By continuously innovating and introducing new products to the pet-care market, the company is positioned to increase its popularity and expand its customer base.
PETQ's total net sales increased 4.6% year-over-year to $328.94 million for the fiscal 2024 second quarter, which ended on July 30. Its gross profit rose 19.5% from the year-ago value to $88.28 million.
Moreover, the company's operating income came in at $25.58 million, increasing 36.7% from the prior year's quarter. Plus, its adjusted EBITDA was reported to be $39.04 million, indicating an increase of 18.8% year-over-year.
In addition, the company's adjusted net income came in at $24.42 million or $0.70 per share, up 82.2% and 52.2% from the prior year's quarter, respectively.
The consensus revenue and EPS estimates of $1.16 billion and $1.56 for the fiscal year ending December 2024 exhibit a year-over-year rise of 4.9% and 25.6%, respectively. Moreover, the company has topped the consensus EPS estimates in all the four trailing quarters.
Shares of PETQ have gained 47.8% over the past three months and 81.8% over the past six months to close the trading session at $30.52.
PETQ's solid fundamentals are echoed in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PETQ has an A grade for Growth and a B for Value. It is ranked #19 out of 62 stocks in the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry.
Beyond what is stated above, we've also rated PETQ for Sentiment, Stability, Momentum, and Quality. Get all PETQ ratings <a href="https://stocknews.com/stock/PETQ/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
ZTS shares were unchanged in premarket trading Thursday. Year-to-date, ZTS has declined -4.37%, versus a 16.65% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/zts-chwy-petq-pahc-3-pet-care-stocks-with-tail-wagging-potential/>3 Pet Care Stocks With Tail-Wagging Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pet Care Stocks With Tail-Wagging Potential

50 stocks to invest during the bull steepening – Part 1

AAPL

ALLE

AMAT

AMCR

AMGN

AMSF

BOTJ

BWXT

CBSH

CCBG

CCOI

CHRW

CHWY

CNOB

COST

CTAS

DXCM

EBMT

EBTC

EXPO

FAST

FRME

GEHC

GOLF

GRMN

HOMB

INGR

INTU

ISRG

JKHY

KLAC

LANC

LDOS

LECO

LFUS

MAIN

MATX

MBWM

MCHP

MDLZ

MKTX

MNST

MPWR

MSCI

MSEX

MSFT

MTRN

MUSA

NDSN

NRIM

NTES

NXPI

ODFL

OTIS

PAHC

PATK

PAYX

PETQ

POOL

PPLL

QCOM

RACE

ROST

SBSI

SIGI

SIRI

SOJC

TCBK

TSCO

UNTY

VEEV

VLTO

WAFD

WING

WSBC

WTRG

Legal

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS

Zoetis Foundation and Zoetis Deepen Commitment to Global Disaster Relief with American Red Cross and American Humane

Zoetis to Host Webcast and Conference Call on Second Quarter 2024 Financial Results

Zoetis Announces Time Change for Second Quarter 2024 Financial Results Webcast and Conference Call

Zoetis Announces Authorization of Multi-Year $6 Billion Share Repurchase Program

Zoetis Announces Second Quarter 2024 Results

Small Cap

Opinion

Sustainable Agriculture: The Growing Need for Biotech Innovations in the World's Food Supplies

Zoetis to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Zoetis to Host Webcast and Conference Call on Third Quarter 2024 Financial Results

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Zoetis

Zoetis (ZTS) Forecast

Zoetis (NYSE:ZTS) Stock, Quote.Headers.trade-ideas